Suppression of Lipopolysaccharide‐Induced Sepsis by Tetrahedral Framework Nucleic Acid Loaded with Quercetin

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Sepsis has affected millions of people worldwide with high mortality rate and lack of effective strategies. Previous studies have reported that quercetin (Que) can attenuate lipopolysaccharide (LPS)‐Induced sepsis. However, for poor water solubility, low bioavailability, and instability, the application of Que is limited. Hence, a nano‐system is constructed to deliver Que based on tetrahedral framework nucleic acid (tFNA), namely tFNA‐Que. For the anti‐inflammatory, anti‐oxidant, and delivery performance of tFNA, tFNA is designed as the effective carrier to deliver Que. The tFNA‐Que possesses the simple synthesis method, stable performance, good biocompatibility, favorable water solubility, excellent anti‐inflammatory, and anti‐oxidation property. As a result, tFNA‐Que can attenuate LPS‐Induced systemic inflammation and multiple organ injury of mice. In brief, the synthesis of tFNA‐Que provides a simple and effective synergistic delivery nano‐system, which may be a promising candidate for sepsis.

Related collections

Most cited references 60

Record: found
Abstract: found
Article: not found

Sepsis and septic shock

Laura Evans, Mitchell Levy, Andrew Rhodes … (2018)

Sepsis is a common condition that is associated with unacceptably high mortality and, for many of those who survive, long-term morbidity. Increased awareness of the condition resulting from ongoing campaigns and the evidence arising from research in the past 10 years have increased understanding of this problem among clinicians and lay people, and have led to improved outcomes. The World Health Assembly and WHO made sepsis a global health priority in 2017 and have adopted a resolution to improve the prevention, diagnosis, and management of sepsis. In 2016, a new definition of sepsis (Sepsis-3) was developed. Sepsis is now defined as infection with organ dysfunction. This definition codifies organ dysfunction using the Sequential Organ Failure Assessment score. Ongoing research aims to improve definition of patient populations to allow for individualised management strategies matched to a patient's molecular and biochemical profile. The search continues for improved diagnostic techniques that can facilitate this aim, and for a pharmacological agent that can improve outcomes by modifying the disease process. While waiting for this goal to be achieved, improved basic care driven by education and quality-improvement programmes offers the best hope of increasing favourable outcomes.

0 comments Cited 830 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

The immunopathology of sepsis and potential therapeutic targets

Tom van der Poll, Frank van de Veerdonk, Brendon P. Scicluna … (2017)

Sepsis — which is caused by a dysregulated host response to infection — is a life-threatening organ dysfunction. This Review describes the recent advances in our understanding of sepsis pathogenesis and discusses strategies for the development of successful therapies.

0 comments Cited 615 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation

Jun Hu, Xing Liu, Shiyu Xia … (2020)

Cytosolic sensing of pathogens and damage by myeloid and barrier epithelial cells assembles large complexes called inflammasomes, which activate inflammatory caspases to process cytokines (IL-1β) and gasdermin D (GSDMD). Cleaved GSDMD forms membrane pores, leading to cytokine release and inflammatory cell death (pyroptosis). Inhibiting GSDMD is an attractive strategy to curb inflammation. Here we identify disulfiram, a drug for treating alcohol addiction, as an inhibitor of pore formation by GSDMD, but not other members of the GSDM family. Disulfiram blocks pyroptosis and cytokine release in cells and lipopolysaccharide (LPS)-induced septic death in mice. At nanomolar concentration, disulfiram covalently modifies human/mouse Cys191/Cys192 in GSDMD to block pore formation. Disulfiram still allows IL-1β and GSDMD processing, but abrogates pore formation, thereby preventing IL-1β release and pyroptosis. The role of disulfiram in inhibiting GSDMD provides new therapeutic indications for repurposing this safe drug to counteract inflammation, which contributes to many human diseases.

0 comments Cited 468 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Contributors

Yunfeng Lin: (View ORCID Profile)

Journal

Title: Advanced Functional Materials

Abbreviated Title: Adv Funct Materials

Publisher: Wiley

ISSN (Print): 1616-301X

ISSN (Electronic): 1616-3028

Publication date Created: October 2022

Publication date (Electronic): August 15 2022

Publication date (Print): October 2022

Volume: 32

Issue: 43

Affiliations

[1 ] State Key Laboratory of Oral Diseases National Clinical Research Center for Oral Diseases West China Hospital of Stomatology Sichuan University Chengdu 610041 P. R. China

[2 ] College of Biomedical Engineering Sichuan University Chengdu 610041 P. R. China

Article

DOI: 10.1002/adfm.202204587

SO-VID: 9f0ff06c-9a33-4840-aba3-9ef1bae98878

License:

http://onlinelibrary.wiley.com/termsAndConditions#vor

History

Data availability:

Comments

Comment on this article

scite_

Smart Citations

Citing PublicationsSupportingMentioningContrasting

View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.